Avience Biomedicals Ltd

₹ 260 3.40%

24 Jul - close price

About

Incorporated in June 2024, Avience Biomedicals Limited is an ISO certified company specializing in manufacturing, supplying, and exporting molecular diagnostic solutions.^[1]

Key Points

Business Profile:^[1]
Avience Biomedicals Limited, incorporated
during the COVID-19 pandemic, is a Noida
based manufacturer of In-Vitro Diagnostic
(IVD) products and medical devices, recognized as a Startup and Small-Scale Industry under MSME.

Website NSE - SM

Market Cap ₹ 142 Cr.
Current Price ₹ 260
High / Low ₹ 415 / 222
Stock P/E 21.2
Book Value ₹
Dividend Yield 0.00 %
ROCE 25.1 %
ROE 28.3 %
Face Value ₹ 10.0

Add ratio to table

Edit ratios

Pros

Company has a good return on equity (ROE) track record: 3 Years ROE 32.8%

Cons

Company might be capitalizing the interest cost
Debtor days have increased from 95.4 to 118 days.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Healthcare Equipment & Supplies Medical Equipment & Supplies

Edit Columns

Loading peers table ...

Detailed Comparison with:

Half Yearly Results

Standalone Figures in Rs. Crores / View Consolidated

	Mar 2025	Sep 2025	Mar 2026
	15.26	19.25	16.07
	10.93	13.87	10.54
Operating Profit	4.33	5.38	5.53
OPM %	28.37%	27.95%	34.41%
	0.47	0.06	0.12
Interest	0.25	0.26	0.37
Depreciation	0.40	0.44	0.53
Profit before tax	4.15	4.74	4.75
Tax %	27.47%	25.32%	32.63%
	3.02	3.54	3.19
EPS in Rs	7.49	8.78	7.91
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	10.15	10.92	16.13	28.63	35.31
	8.93	9.49	12.88	20.95	24.41
Operating Profit	1.22	1.43	3.25	7.68	10.90
OPM %	12.02%	13.10%	20.15%	26.83%	30.87%
	-0.00	0.01	0.38	0.57	0.18
Interest	0.16	0.27	0.44	0.64	0.62
Depreciation	0.09	0.20	0.44	0.75	0.98
Profit before tax	0.97	0.97	2.75	6.86	9.48
Tax %	24.74%	18.56%	26.91%	27.11%	29.01%
	0.72	0.78	2.00	5.00	6.73
EPS in Rs	3.54	2.37	6.09	12.40	16.69
Dividend Payout %	-0.00%	-0.00%	-0.00%	-0.00%	-0.00%

Compounded Sales Growth
10 Years:	%
5 Years:	%
3 Years:	48%
TTM:	23%

Compounded Profit Growth
10 Years:	%
5 Years:	%
3 Years:	105%
TTM:	33%

Stock Price CAGR
10 Years:	%
5 Years:	%
3 Years:	%
1 Year:	%

Return on Equity
10 Years:	%
5 Years:	32%
3 Years:	33%
Last Year:	28%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	2.03	3.28	3.28	4.03	4.03
Reserves	0.76	0.79	2.78	16.37	23.11
	2.49	2.66	7.73	13.74	19.06
	0.82	3.29	11.82	9.42	11.81
Total Liabilities	6.10	10.02	25.61	43.56	58.01
	1.17	2.52	6.80	8.82	24.34
CWIP	-0.00	-0.00	0.03	4.62	-0.00
Investments	-0.00	-0.00	5.73	5.73	5.73
	4.93	7.50	13.05	24.39	27.94
Total Assets	6.10	10.02	25.61	43.56	58.01

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

	Mar 2022	Mar 2023	Mar 2024	Mar 2025
	-1.96	1.74	0.23	3.14
	-0.89	-1.94	-4.12	-8.16
	2.79	0.43	3.80	9.06
Net Cash Flow	-0.06	0.24	-0.09	4.04
Free Cash Flow	-2.83	0.05	-3.70	-4.74
CFO/OP	-148%	134%	11%	49%

Ratios

Standalone Figures in Rs. Crores / View Consolidated

	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor Days	90.98	56.82	54.76	113.34	118.26
Inventory Days	71.44	166.08	269.38	172.84	194.49
Days Payable	11.18	59.58	143.60	106.17	97.24
Cash Conversion Cycle	151.25	163.32	180.54	180.01	215.50
Working Capital Days	52.14	25.07	-140.30	22.69	15.51
ROCE %		20.65%	30.99%	31.59%	25.14%

Shareholding Pattern

Numbers in percentages

18 Recently

	Jun 2026
	64.59%
	3.06%
	9.08%
	23.26%
No. of Shareholders	630

	Jun 2026
	64.59%
	3.06%
	9.08%
	23.26%
No. of Shareholders	630

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

All

Annual reports

No data available.

Concalls

Jul 2026

Transcript

AI Summary
PPT